Diligence memo · auto-generated · as of July 2, 2026
Alvine Pharmaceuticals Inc
Alvine Pharmaceuticals Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Alvine Pharmaceuticals Inc operates in Other Health Care, based in SAN CARLOS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Alvine Pharmaceuticals Inc has raised $47M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $27M on 2009-09-04.
Most recent recorded round closed around 2012-12-19.
Valuation (modeled)modeled
Provath models Alvine Pharmaceuticals Inc at approximately $133M (range $14M–$512M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.31× the median modeled value of Series B Other Health Care companies in 2010–2012 (50 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 13.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 92% of Other Health Care peers (5377 compared).
Modeled value ranks above 83% of those peers.
Closest niche peers: Cell MDX, LLC, OptiMedica Corp, Riverchase Holdings Mso, Llc, CDRT Holding Corp, Pivot Medical Inc.
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.